GeoVax Labs (GOVX)

• Market cap: $20.9M
• 1 day: 0.00%
• 5 days: 3.26%
• 1 month: 0.45%
• 3 months: -0.89%
• 6 months: -16.85%
• Year to date: -10.48%
• 1 year: -48.61%
• 5 years: -94.97%
• 10 years: -94.97%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Employees: 17

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

58% more capital invested

Capital invested by funds: $624K [Q2] → $985K (+$362K) [Q3]

42% more funds holding

Funds holding: 12 [Q2] → 17 (+5) [Q3]

2.47% less ownership

Funds ownership: 7.74% [Q2] → 5.26% (-2.47%) [Q3]

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 260% upside
• Avg. target: $13.67 516% upside
• High target: $18 711% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 39% 1-year accuracy 76 / 193 met price target	711% upside $18	Buy Maintained	16 Jan 2025
HC Wainwright & Co. Vernon Bernardino 37% 1-year accuracy 22 / 59 met price target	260% upside $8	Buy Reiterated	20 Nov 2024
Alliance Global Partners James Molloy 20% 1-year accuracy 2 / 10 met price target	576% upside $15	Buy Initiated	11 Nov 2024